Baheal Pharmaceutical Gains Exclusive Rights to Roche’s MabThera in China
China-based health services and distribution giant Baheal Pharmaceutical Group (SHE: 301015) last month reached an...
Zhejiang Huahai’s HB0034 Meets Primary Endpoint in GPP Study
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that its multi-center, double-blinded, randomized, placebo-parallel...
CStone Pharmaceuticals and SteinCares Ink Licensing Deal for PD-L1 Inhibitor in Latin America
China-based CStone Pharmaceuticals (HKG: 2616) and Costa Rica-based drug maker and distributor SteinCares have entered...
Fosun Pharma’s 24-Valent Pneumococcal Vaccine Receives NMPA Approval for Phase I Trial
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd’s (SHA: 600196, HKG: 2196) subsidiary Fosun Adgenvax (Chengdu)...
Bio-Thera Solutions Inks Licensing Deal with World Medicine for BAT2206
China-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with World Medicine, granting...
Hainan Poly Pharm’s US Partner Slate Run Pharmaceuticals Collaborates with Premier on Contrast Agents
China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) announced a significant partnership between its US...
Gensaic and Novo Nordisk Team Up to Develop Cardiometabolic Therapies
US-based AI-powered biotech Gensaic, Inc. announced the signing of a licensing and discovery cooperation agreement...
MSD China Reorganizes to Boost Mature Product Lines
Anna Van Acker, Senior Vice-President of Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) and...
Suzhou Abogen’s RSV mRNA Vaccine IND Approved by China’s CDE
China-based nucleic acid drug developer Suzhou Abogen Biosciences announced that the Investigational New Drug (IND)...
CDE Launches SPARK Project to Boost Pediatric Antitumor Drug R&D
China’s Center for Drug Evaluation (CDE) has released a notification to solicit feedback on its...
BeiGene’s Tevimbra Receives FDA Approval for ESCC Treatment
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a multinational oncology company planning to change...
Organon’s 2024 Financial Report Shows Steady Growth in Women’s Health and Biosimilars
Women’s health specialist Organon (NYSE: OGN) released its 2024 financial report, showing a 3% year-on-year...
AstraZeneca and Daiichi Sankyo’s Enhertu Shows Positive Results in Phase III Study
Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced positive topline results from the...
Boehringer Ingelheim Appeals CNIPA’s Invalidation of Jardiance Patents
The Intellectual Property Court of the Supreme People’s Court of China issued a notice, holding...
Genentech’s TNKase Approved by FDA for Acute Ischemic Stroke Treatment
Genentech, a subsidiary of Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY), announced that its thrombolytic...
Eisai’s Lecanemab Rejected by Australia’s TGA for Early Alzheimer’s Treatment
Japan-based Eisai Co., Ltd (TYO: 4523) announced that the Therapeutic Goods Administration (TGA) of Australia...
Boston Scientific to Acquire SoniVie, Boosting Hypertension Treatment Portfolio
Boston Scientific Corporation (NYSE: BSX) is set to acquire SoniVie Ltd, an Israel-based medical device...
Fapon Biopharma’s FP008 Receives FDA Approval for Clinical Trials
China-based Fapon Biopharma announced that it has received clinical trial approval from the US Food...
Kyorin Pharmaceutical Licenses KRP-M223 to Novartis for Global Development
Japan-based Kyorin Pharmaceutical Co., Ltd. announced a licensing agreement with Novartis (NYSE: NVS), granting the...
GSK’s Depemokimab Accepted for FDA Review as Ultra-Long-Acting Biologic
GSK plc (LON: GSK, NYSE: GSK) announced that the US Food and Drug Administration (FDA)...